Pfizer

B8011006

NCT04165317

JCP076

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)

Status:

Opening Soon

26459-200.png

III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Sasanlimab (PF-06801591)

Anti-programmed cell death 1 (PD-1) receptor antibody

Treatment Arms

o  Experimental Arm 1: PF-06801591 + BCG induction and maintenance

o  Experimental Arm 2: PF-06801591 + BCG induction only

o  Active Comparator: BCG induction and maintenance